Open an account

Relay Therapeutics

RLAY · NASDAQ

$18.45+$1.36 (+7.96%)TodayMarket closed ·
Prev close $17.09

About RLAY

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2020-07-16. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. The company is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

Employees
192
Headquarters
Cambridge, Massachusetts
Listed
Jul 16, 2020
Sector
Health Care
Industry
Biotechnology
Website
relaytx.com

RLAY key statistics

Market cap
4.04B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.97M
Volume
1.98M
Open price
$17.03
High today
$18.69
Low today
$17.01
52 Week high
$21.27
52 Week low
$5.95

Relay Therapeutics (RLAY) at a glance

As of Oct 20, 2026, Relay Therapeutics (RLAY) shares are priced at $18.45, giving the company a market cap of 4.04B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $17.01 and $18.69. The current price is 8.5% above the day's low and 1.3% below its high.

Volume so far is 1.98M shares, below the average of 2.97M shares a day.

Over the past year Relay Therapeutics has ranged from $5.95 to $21.27, and now sits 82% of the way up that range.

Relay Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.41 per share against an estimate of -$0.3989.

The average analyst price target is $27.82, 50.8% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

91%of 11 analyst ratings say Buy
  • Buy90.9%
  • Hold9.1%
  • Sell0.0%
Price target · 14 analystsAvg $27.82
Low
$20.20
Now
$18.45
High
$33.60

RLAY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 17.8% on average.

  1. Q3 FY24: reported -$0.63 per share against an estimate of -$0.7829
  2. Q4 FY24: reported -$0.45 per share against an estimate of -$0.573
  3. Q1 FY25: reported -$0.46 per share against an estimate of -$0.4978
  4. Q2 FY25: reported -$0.41 per share against an estimate of -$0.5014
  5. Q3 FY25: reported -$0.43 per share against an estimate of -$0.4238
  6. Q4 FY25: reported -$0.32 per share against an estimate of -$0.4124
  7. Q1 FY26: reported -$0.41 per share against an estimate of -$0.3844
  8. Q2 FY26: reported -$0.41 per share against an estimate of -$0.3989

RLAY news

  • Press releaseGlobe Newswire

    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

  • Press releasePRNewswire

    An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

  • Press releaseGlobe Newswire

    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

  • Vandana Singh

    Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders

  • Press releaseGlobe Newswire

    Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

  • Press releaseGlobe Newswire

    Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releasePRNewswire

    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

Similar companies

Companies in the same industry as Relay Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.